Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Zacks.com on MSN1h
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...
As a young life sciences company seeks to establish its ... Many variables can throw a timeline off course, whether it’s a partner taking too long to review a joint press release or a key ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback